| Do patients with cancer have a poorer prognosis of COVID-19? An experience in New York City H Miyashita, T Mikami, N Chopra, T Yamada, S Chernyavsky, D Rizk, ... Annals of Oncology 31 (8), 1088-1089, 2020 | 432 | 2020 |
| Risk factors for mortality in patients with COVID-19 in New York City T Mikami, H Miyashita, T Yamada, M Harrington, D Steinberg, A Dunn, ... Journal of general internal medicine 36, 17-26, 2021 | 312 | 2021 |
| Value of leukocytosis and elevated C-reactive protein in predicting severe coronavirus 2019 (COVID-19): A systematic review and meta-analysis T Yamada, M Wakabayashi, T Yamaji, N Chopra, T Mikami, H Miyashita, ... Clinica chimica acta 509, 235-243, 2020 | 113 | 2020 |
| Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic … T Yamada, M Wakabayashi, A Bhalla, N Chopra, H Miyashita, T Mikami, ... Cardiovascular diabetology 20, 1-13, 2021 | 108 | 2021 |
| Patients with chronic kidney disease have a poorer prognosis of coronavirus disease 2019 (COVID-19): an experience in New York City T Yamada, T Mikami, N Chopra, H Miyashita, S Chernyavsky, S Miyashita International Urology and Nephrology 52, 1405-1406, 2020 | 58 | 2020 |
| First-in-class humanized FSH blocking antibody targets bone and fat S Gera, D Sant, S Haider, F Korkmaz, TC Kuo, M Mathew, H Perez-Pena, ... Proceedings of the National Academy of Sciences 117 (46), 28971-28979, 2020 | 42 | 2020 |
| Impact of dementia on clinical outcomes in elderly patients with coronavirus 2019 (COVID-19): an experience in New York. S Miyashita, T Yamada Geriatrics & gerontology international 20 (7), 2020 | 40 | 2020 |
| An evaluation of serum 25-hydroxy vitamin D levels in patients with COVID-19 in New York City EM Gavioli, H Miyashita, O Hassaneen, E Siau Journal of the American Nutrition Association 41 (2), 201-206, 2022 | 38 | 2022 |
| Repurposing erectile dysfunction drugs tadalafil and vardenafil to increase bone mass SM Kim, C Taneja, H Perez-Pena, V Ryu, A Gumerova, W Li, N Ahmad, ... Proceedings of the National Academy of Sciences 117 (25), 14386-14394, 2020 | 21 | 2020 |
| Effect of exposure to Agent Orange on the risk of monoclonal gammopathy and subsequent transformation to multiple myeloma: a single-center experience from the Veterans Affairs … N Bumma, M Nagasaka, G Hemingway, H Miyashita, T Chowdhury, S Kim, ... Clinical Lymphoma Myeloma and Leukemia 20 (5), 305-311, 2020 | 16 | 2020 |
| Bone modifying agents for bone loss in patients with aromatase inhibitor as adjuvant treatment for breast cancer; insights from a network meta-analysis H Miyashita, S Satoi, T Kuno, C Cruz, S Malamud, SM Kim Breast cancer research and treatment 181, 279-289, 2020 | 15 | 2020 |
| Network meta-analysis of anticoagulation strategies for venous thromboembolism in patients with cancer H Ueyama, H Miyashita, H Takagi, C Cruz, A Burger, A Briasoulis, T Kuno Journal of Thrombosis and Thrombolysis 51, 102-111, 2021 | 13 | 2021 |
| LAG‐3 transcriptomic expression patterns across malignancies: Implications for precision immunotherapeutics JJ Adashek, S Kato, D Nishizaki, H Miyashita, P De, S Lee, S Pabla, ... Cancer Medicine 12 (12), 13155-13166, 2023 | 10 | 2023 |
| Incidence and risk of colitis with programmed death 1 versus programmed death ligand 1 inhibitors for the treatment of cancer H Miyashita, T Mikami, S Satoi, C Cruz, MD Galsky Journal of Immunotherapy 43 (9), 291-298, 2020 | 10 | 2020 |
| Risk factors for skeletal-related events in patients with bone metastasis from breast cancer undergoing treatment with zoledronate H Miyashita, C Cruz, S Malamud Breast cancer research and treatment 182, 381-388, 2020 | 10 | 2020 |
| Risk factors of skeletal-related events in patients with bone metastasis from non-small cell lung cancer undergoing treatment with zoledronate—a post hoc analysis of a … H Miyashita, C Cruz, C Smith Supportive Care in Cancer 29, 1629-1633, 2021 | 8 | 2021 |
| T-cell priming transcriptomic markers: implications of immunome heterogeneity for precision immunotherapy H Miyashita, R Kurzrock, NJ Bevins, K Thangathurai, S Lee, S Pabla, ... NPJ Genomic Medicine 8 (1), 19, 2023 | 7 | 2023 |
| Incidence of hepatotoxicity associated with addition of immune checkpoint blockade to systemic solid tumor therapy: a meta-analysis of phase 3 randomized controlled trials Y Fujiwara, N Horita, M Harrington, H Namkoong, H Miyashita, MD Galsky Cancer Immunology, Immunotherapy 71 (12), 2837-2848, 2022 | 6 | 2022 |
| Risk factors of skeletal-related events in patients with bone metastatic castration-resistant prostate cancer undergoing treatment with zoledronate H Miyashita, C Cruz, V Patel Supportive Care in Cancer 30, 981-984, 2022 | 5 | 2022 |
| Neo‐adjuvant therapy for triple‐negative breast cancer: Insights from a network meta‐analysis H Miyashita, S Satoi, C Cruz, SC Malamud The Breast Journal 26 (9), 1717-1728, 2020 | 5 | 2020 |
